Sionna Therapeutics (SION) Q4 2025 earnings summary

Executive summary

• Advanced two NBD1 stabilizer programs (SION-719 and SION-451) into new clinical trials, with topline data expected mid-2026.

• Presented positive Phase 1 data and new preclinical results at a major cystic fibrosis conference.

• Maintained a strong cash position, supporting operations into 2028.

Financial highlights

• Research and development expenses rose to $15.2M for Q4 2025 and $60.3M for the year, up from $14.3M and $57.3M in 2024.

• General and administrative expenses increased to $8.4M for Q4 and $28.7M for the year, compared to $3.9M and $13.3M in 2024.

• Net loss was $20.4M for Q4 2025 and $75.3M for the year, compared to $15.8M and $61.7M in 2024.

• Cash, cash equivalents, and marketable securities totaled $310.3M as of December 31, 2025.

Outlook and guidance

• Topline data from ongoing Phase 2a and Phase 1 trials expected in mid-2026.

• Current cash position expected to fund operations into 2028.